- Home
- XOMAP vs WDAY Comparison
XOMAP vs WDAY Comparison
Compare XOMAP & WDAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- WDAY
- Stock Information
- Founded
- XOMAP N/A
- WDAY 2005
- Country
- XOMAP United States
- WDAY United States
- Employees
- XOMAP 13
- WDAY N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- WDAY EDP Services
- Sector
- XOMAP Health Care
- WDAY Technology
- Exchange
- XOMAP Nasdaq
- WDAY Nasdaq
- Market Cap
- XOMAP N/A
- WDAY N/A
- IPO Year
- XOMAP N/A
- WDAY 2012
- Fundamental
- Price
- XOMAP $25.55
- WDAY $213.22
- Analyst Decision
- XOMAP
- WDAY Buy
- Analyst Count
- XOMAP 0
- WDAY 27
- Target Price
- XOMAP N/A
- WDAY $301.08
- AVG Volume (30 Days)
- XOMAP N/A
- WDAY 2.6M
- Earning Date
- XOMAP N/A
- WDAY 08-21-2025
- Dividend Yield
- XOMAP N/A
- WDAY N/A
- EPS Growth
- XOMAP N/A
- WDAY N/A
- EPS
- XOMAP N/A
- WDAY 1.81
- Revenue
- XOMAP N/A
- WDAY $8,696,000,000.00
- Revenue This Year
- XOMAP N/A
- WDAY $14.87
- Revenue Next Year
- XOMAP N/A
- WDAY $13.05
- P/E Ratio
- XOMAP N/A
- WDAY $117.98
- Revenue Growth
- XOMAP N/A
- WDAY 14.95
- 52 Week Low
- XOMAP N/A
- WDAY $205.33
- 52 Week High
- XOMAP N/A
- WDAY $294.00
- Technical
- Relative Strength Index (RSI)
- XOMAP 44.91
- WDAY 29.13
- Support Level
- XOMAP $25.65
- WDAY $217.62
- Resistance Level
- XOMAP $25.87
- WDAY $223.27
- Average True Range (ATR)
- XOMAP 0.04
- WDAY 6.33
- MACD
- XOMAP -0.02
- WDAY -2.10
- Stochastic Oscillator
- XOMAP 0.00
- WDAY 3.08
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.